IMAXT and Rosetta: the teams that took on the 3D tumour mapping challenge
Learn about how IMAXT and Rosetta have been at the forefront of the spatial biology revolution.
Impact
Changing the landscape of cancer research
From transforming our understanding of the role of mutations in cancer to developing cutting-edge technologies to comprehensively map tumours, Cancer Grand Challenges teams are driving impact against some of the toughest challenges in cancer.
In 2017, we awarded over $90m of funding to four teams to take on our first round of challenges — 3D tumour mapping, lethal versus non-lethal cancers and unusual mutation patterns. In the seven years that followed, these teams made incredible progress; changing ways of thinking in their fields and paving the way for future research, to ultimately change outcomes for people with cancer.
Since 2017 we have funded 16 teams to solve 13 of cancer’s toughest challenges, investing over $400m in funding and further demonstrating the potential of interdisciplinary team science and collaboration across borders to deliver transformative advances.
Learn more about the impact of our concluded teams below.
Discover: A year of scientific creativity
Cancer Grand Challenges' annual progress magazine, highlighting the latest progress from funded teams, stories from the community and more.
Read the magazine 